BCM
TXMD icon

Brookstone Capital Management’s TherapeuticsMD TXMD Stock Holding History

Brookstone Capital Management’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-306
Closed -$21K – 757
2021
Q1 		$21K Sell
306
-120
-28% -$9.39K ﹤0.01% 502
2020
Q4 		$26K Buy
426
+48
+13% +$3.28K ﹤0.01% 467
2020
Q3 		$30K Buy
378
+140
+59% +$11.2K ﹤0.01% 439
2020
Q2 		$15K Buy
+238
New +$13.9K ﹤0.01% 354

Other funds holding TXMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Brookstone Capital Management's TXMD Position: Q2 2021 in Review

Brookstone Capital Management sold out of TherapeuticsMD (TXMD) in Q2 2021, closing a stake of 306 shares — an estimated $21K sold.

Brookstone Capital Management first reported a position in TXMD in Q2 2020 and held it in 4 quarters. The position peaked at $30K in Q3 2020. 154 funds tracked by Wall St. Rank hold TXMD as of Q2 2021.

  • Brookstone Capital Management reported no remaining TherapeuticsMD position as of Q2 2021 after selling out during the quarter.
  • Brookstone Capital Management sold 306 TherapeuticsMD shares in Q2 2021, an estimated $21K.
  • Brookstone Capital Management first reported a position in TherapeuticsMD in Q2 2020 and held it in 4 quarters.
  • Brookstone Capital Management's TherapeuticsMD position peaked at $30K in Q3 2020.
  • 154 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2021.

Based on Brookstone Capital Management's 13F filing for Q2 2021, filed 14 Jul 2021.